Dear Colleague,

With omics based technologies, novel genes and potential candidate proteins can be quickly identified. However, the discovery of viable drug targets still remains a challenge in the genomic and proteomic field while regulatory and ethical issues continue to hinder the process of bringing drugs into the market. Meanwhile, pharmacogenomic studies remain at the forefront for developing personalized medicine.

GTC’s 2nd Genomic & Proteomic Drug Discovery Conference is a 2-day meeting to be held on May 30-31, at the Hyatt Harborside in Boston, MA. Additionally, there will be a supplementary Clinical Sequencing Workshop to be held on May 29th. The conference will be a forum for the use of omics based methods such as next generation sequencing and mass spectrometry for biomarker discovery and the development of novel therapeutics. Technology, diagnostics and major pharmaceuticals such as Pfizer, Roche, Novartis, GlaxoSmithKline, Merck , Genzyme, Life Technologies, Agilent and more will meet with academic and government experts to discuss the novel applications of omics based research and its implications toward personalized medicine.

Sessions for the conference:

Pharmaco-omics
- Personalized medicine
- Biomarkers for stratifying patient groups
Advances in Genomic Medicine
Identification and Validation of Drug Targets
Systems Biology for Therapeutic & Diagnostic Discovery
- Mass Spectrometry-based Biomarker Discovery

The 2nd Genomic & Proteomic Drug Discovery Conference is part of the Omics Evolution Summit, which includes 6 co-located conferences and a Clinical Sequencing Workshop on May 29th. Register for the entire summit and have access to the all of the following conferences:

2nd Next Generation Sequencing
2nd Epigenetics in Drug Discovery Conference
3rd RNAi Research and Development Conference
7th Protein Kinases in Drug Discovery Conference

Genome-wide Partnering and Deal Making Conference

We look forward to seeing you at the conference!